The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The head and neck cancer market has been comprehensively analyzed in IMARC’s new report titled “Head and Neck Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”. Head and neck cancer refers to the term used to describe a variety of malignant tumors that develop in or around the throat, larynx, sinuses, nose, and mouth. Such forms of cancer are hard to diagnose, and the symptoms are very mild. These cancers can mimic less severe conditions such as cold and sore throat, and the symptoms may include a mouth or tongue sore that does not heal on its own, a white or a red patch on the gums, tongue, or the lining area of the mouth, a persistent sore throat, and hoarseness. Head and neck cancer can be hard to diagnose and early detection is necessary to successfully treat both cancers. Some of the techniques that are advised for diagnosing head and neck malignancies include a physical exam that may be used to check on the oral and nasal cavities, an endoscopic examination, and laboratory testing using blood, urine, and other body samples. Other tests include head and neck X-rays, CAT scans, MRIs, and PET scans to view images inside the neck and head. The two primary treatment modalities are surgery and radiotherapy. Clinical results have improved due to better surgical and radiation treatment approaches and the use of systemic medicines in curative therapy.
The increasing prevalence of head and neck cancer on account of the rising consumption of alcoholic beverages and tobacco-based products is primarily driving the head and neck cancer market. In line with this, the growing incidences of infectious diseases (human papillomavirus/Epstein bar virus), nutritional deficiencies, and underlying genetic disorders are further augmenting the market growth. Moreover, the emerging popularity of cancer immunotherapy owing to the growing awareness regarding its efficacy and fewer side effects as compared to traditional chemotherapy is also creating a positive outlook for the market. Additionally, the introduction of advanced oncological imaging modalities and imaging technologies to detect infections with enhanced accuracy is further bolstering the global market. Besides this, several key players are making significant investments to produce cancer vaccines and novel biomarkers for the identification of potential tumors. This, in turn, is also acting as another growth-inducing factor. Moreover, the launch of favorable initiatives by various non-governmental organizations (NGOs) and healthcare practitioners to sensitize individuals about the benefits of early cancer diagnosis, including instant decision-making and consequent treatment, is further fueling the market growth. Numerous other factors, such as the increasing regulatory approvals for new cancer immunotherapy drugs, technological advancements in clinical therapies, and the emerging popularity of targeted molecular therapy, including gene therapy, monoclonal antibodies, antibody drug conjugates, etc., are expected to drive the global head and neck cancer market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the head and neck cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for head and neck cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the head and neck cancer market in any manner.
Time Period of the Study
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current head and neck cancer marketed drugs and late-stage pipeline drugs.
Late-Stage Pipeline Drugs
Head and Neck Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
Pregnancy Detection Kits Market by Product (Home Pregnancy Tests (HPT), Digital Devices, and Others), Test Type (Urine Test for HCG, Blood Test for HCG, and Others), End User (Household, Gynecology Clinics, Hospitals), and Region 2023-2028
Swine Healthcare Market by Product (Diagnostic Tests, Therapeutics), Disease (Exudative Dermatitis, Coccidiosis, Respiratory Diseases, Swine Dysentery, Porcine Parvovirus, and Others), Route of Administration (Injectable, Oral), Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Online Pharmacy), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at